COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Rating of “Moderate Buy” from Analysts

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $16.25.

Several research firms have commented on CMPS. BTIG Research upped their price objective on COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Royal Bank Of Canada upped their price target on COMPASS Pathways from $16.00 to $21.00 and gave the stock an “outperform” rating in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday. Finally, Morgan Stanley boosted their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th.

Institutional Trading of COMPASS Pathways

A number of institutional investors have recently modified their holdings of the business. Nantahala Capital Management LLC raised its position in COMPASS Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after acquiring an additional 1,350,698 shares in the last quarter. Millennium Management LLC boosted its position in shares of COMPASS Pathways by 39.9% during the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock worth $15,562,000 after purchasing an additional 774,090 shares in the last quarter. UBS Group AG grew its stake in shares of COMPASS Pathways by 27.7% during the 3rd quarter. UBS Group AG now owns 2,144,410 shares of the company’s stock worth $12,287,000 after purchasing an additional 465,802 shares during the period. ARK Investment Management LLC increased its holdings in shares of COMPASS Pathways by 28.6% in the 3rd quarter. ARK Investment Management LLC now owns 2,121,118 shares of the company’s stock valued at $12,154,000 after purchasing an additional 471,897 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of COMPASS Pathways in the third quarter valued at about $7,890,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Trading Up 0.6%

Shares of COMPASS Pathways stock opened at $7.17 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. The company has a market capitalization of $688.46 million, a P/E ratio of -2.64 and a beta of 1.92. COMPASS Pathways has a 1 year low of $2.25 and a 1 year high of $8.20. The company’s fifty day moving average is $6.42 and its two-hundred day moving average is $5.58.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. Analysts forecast that COMPASS Pathways will post -2.33 earnings per share for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.